Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ABP 798 |
Synonyms | |
Therapy Description |
ABP 798 is a putative biosimilar of the anti-CD20 antibody Rituximab (PMID: 29699853). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ABP 798 | ABP-798|ABP798 | CD20 Antibody 24 | ABP 798 is a putative biosimilar of the anti-CD20 antibody Rituximab (PMID: 29699853). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02747043 | Phase III | ABP 798 Rituximab | Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab (JASMINE) | Completed | USA | ROU | POL | ITA | ISR | GRC | FRA | ESP | DEU | CZE | CAN | BGR | AUS | 7 |